The RET G810C secondary mutation was also identified in an NSCLC patient with a CCDC6‐RET fusion who acquired resistance to selpercatinib, and this finding was supported by Ba/F3 cell experiments. This evidence concerns the gene RET and non-small cell lung carcinoma.